Earnings Grew Faster Than the Notable 60% Return Delivered to Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Over the Last Year

Simply Wall St02:26

Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $135

Futu NewsDec 23 20:33 · Ratings

Ligand Pharmaceuticals Is Maintained at Overweight by Barclays

Dow JonesDec 16 22:52 · Ratings

Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $160

Futu NewsDec 16 19:31 · Ratings

Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow JonesDec 11 23:55 · Ratings

Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating

Futu NewsDec 11 22:31 · Ratings